Fate Therapeutics Analyst Price Targets

Wall Street analyst price targets and consensus rating for Fate Therapeutics (FATE).

Price Target Range — 10 Quarters

Analyst Consensus — 11 Analysts

6Buy

4Hold

1Sell

Consensus RatingBuy# Analysts11Avg. Consensus PT$6Upside to Avg. PT+180.5%

Rating Trend — Last 9 Months

Recent Analyst Actions

Ver todas las valoraciones →

Date	Firm	Analyst	Action	Rating Change	Price Target
Aug 14, 2026	Piper Sandler	Edward Tenthoff	PT Raise	Overweight	$6→$8
Aug 14, 2026	Wells Fargo	Yanan Zhu	PT Raise	Equal-Weight	$3→$4
Aug 14, 2026	Wedbush	Martin Fan	Maintained	Outperform	$7
Jun 8, 2026	HC Wainwright & Co.	Robert Burns	Maintained	Buy	$7
May 4, 2026	HC Wainwright & Co.	Robert Burns	PT Raise	Buy	$5→$7
Oct 31, 2025	HC Wainwright & Co.	Robert Burns	Upgrade	Neutral→Buy	$5
Oct 27, 2025	Wedbush	David Nierengarten	Upgrade	Neutral→Outperform	$5→$7
Oct 27, 2025	Needham	Gil Blum	Maintained	Hold	—
Aug 13, 2025	Wells Fargo	Yanan Zhu	PT Cut	Equal-Weight	$4→$3
Jun 12, 2025	Needham	Gil Blum	Maintained	Hold	—
May 14, 2025	Barclays	Peter Lawson	PT Cut	Overweight	$10→$2
May 14, 2025	Baird	Jack Allen	PT Cut	Neutral	$5→$4
May 14, 2025	Needham	Gil Blum	Maintained	Hold	—
Mar 6, 2025	Stifel	Benjamin Burnett	PT Cut	Hold	$5→$3
Mar 6, 2025	Wedbush	David Nierengarten	Maintained	Neutral	$5
Mar 6, 2025	Wells Fargo	Yanan Zhu	PT Cut	Equal-Weight	$5→$4
Mar 6, 2025	Needham	Gil Blum	Maintained	Hold	—
Nov 19, 2024	Needham	Gil Blum	Maintained	Hold	—
Nov 13, 2024	Needham	Gil Blum	Maintained	Hold	—
Aug 22, 2024	HC Wainwright & Co.	Raghuram Selvaraju	Maintained	Neutral	$5

More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Piper Sandler Reiterates Overweight on Fate Therapeutics, Raises Price Target to $8

Piper Sandler analyst Edward Tenthoff reiterates Fate Therapeutics (NASDAQ:FATE) with a Overweight and raises the price target from $6 to $8.

Benzinga Newsdesk

PRO
Wells Fargo Maintains Equal-Weight on Fate Therapeutics, Raises Price Target to $3.5

Wells Fargo analyst Yanan Zhu maintains Fate Therapeutics (NASDAQ:FATE) with a Equal-Weight and raises the price target from $2.5 to $3.5.

Benzinga Newsdesk

PRO
Wedbush Reiterates Outperform on Fate Therapeutics, Maintains $7 Price Target

Wedbush analyst Martin Fan reiterates Fate Therapeutics (NASDAQ:FATE) with a Outperform and maintains $7 price target.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Buy on Fate Therapeutics, Maintains $7 Price Target

HC Wainwright & Co. analyst Robert Burns reiterates Fate Therapeutics (NASDAQ:FATE) with a Buy and maintains $7 price target.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Maintains Buy on Fate Therapeutics, Raises Price Target to $7

HC Wainwright & Co. analyst Robert Burns maintains Fate Therapeutics (NASDAQ:FATE) with a Buy and raises the price target from $5 to $7.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Upgrades Fate Therapeutics to Buy, Maintains Price Target to $5

HC Wainwright & Co. analyst Robert Burns upgrades Fate Therapeutics (NASDAQ:FATE) from Neutral to Buy and maintains the price target from $5 to $5.

Benzinga Newsdesk

Fate Therapeutics Inc

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL

Fate Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
Piper Sandler Reiterates Overweight on Fate Therapeutics, Raises Price Target to $8

PRO
Wells Fargo Maintains Equal-Weight on Fate Therapeutics, Raises Price Target to $3.5

PRO
Wedbush Reiterates Outperform on Fate Therapeutics, Maintains $7 Price Target

PRO
HC Wainwright & Co. Reiterates Buy on Fate Therapeutics, Maintains $7 Price Target

PRO
HC Wainwright & Co. Maintains Buy on Fate Therapeutics, Raises Price Target to $7

PRO
HC Wainwright & Co. Upgrades Fate Therapeutics to Buy, Maintains Price Target to $5

People Also Watch

People Also Watch

Fate Therapeutics Inc

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL

Fate Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROPiper Sandler Reiterates Overweight on Fate Therapeutics, Raises Price Target to $8

PROWells Fargo Maintains Equal-Weight on Fate Therapeutics, Raises Price Target to $3.5

PROWedbush Reiterates Outperform on Fate Therapeutics, Maintains $7 Price Target

PROHC Wainwright & Co. Reiterates Buy on Fate Therapeutics, Maintains $7 Price Target

PROHC Wainwright & Co. Maintains Buy on Fate Therapeutics, Raises Price Target to $7

PROHC Wainwright & Co. Upgrades Fate Therapeutics to Buy, Maintains Price Target to $5

People Also Watch

People Also Watch

PRO
Piper Sandler Reiterates Overweight on Fate Therapeutics, Raises Price Target to $8

PRO
Wells Fargo Maintains Equal-Weight on Fate Therapeutics, Raises Price Target to $3.5

PRO
Wedbush Reiterates Outperform on Fate Therapeutics, Maintains $7 Price Target

PRO
HC Wainwright & Co. Reiterates Buy on Fate Therapeutics, Maintains $7 Price Target

PRO
HC Wainwright & Co. Maintains Buy on Fate Therapeutics, Raises Price Target to $7

PRO
HC Wainwright & Co. Upgrades Fate Therapeutics to Buy, Maintains Price Target to $5